Cargando…

ASCO 2016 – update colorectal liver metastases

This short review summarizes the most relevant data on colorectal liver metastases (CLM) presented at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO). For this update, congress abstracts were grouped into three clinically relevant scenarios: CLM that are deemed upfront re...

Descripción completa

Detalles Bibliográficos
Autor principal: Kaczirek, Klaus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5493718/
https://www.ncbi.nlm.nih.gov/pubmed/28725278
http://dx.doi.org/10.1007/s12254-016-0308-y
_version_ 1783247551754928128
author Kaczirek, Klaus
author_facet Kaczirek, Klaus
author_sort Kaczirek, Klaus
collection PubMed
description This short review summarizes the most relevant data on colorectal liver metastases (CLM) presented at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO). For this update, congress abstracts were grouped into three clinically relevant scenarios: CLM that are deemed upfront resectable, borderline resectable, and primarily unresectable. According to a large registry study, small, upfront resectable, solitary CLM should be resected using a parenchymal sparing technique. A prospective noninterventional study suggested that chemotherapy plus the anti-VEGF (vascular endothelial growth factor) antibody bevacizumab is effective and well tolerated in patients with borderline resectable CLM. In the setting of CLM deemed initially unresectable, a phase 2 study reported superior outcomes in terms of liver metastases resection rates as well as overall survival (OS) in patients receiving a chemotherapy triplet (FOLFIRINOX) plus a targeted agent as compared to FOLFIRI or FOLFOX4 with the same targeted therapy. Finally, a study suggested that tailoring first-line chemotherapy according to TYMS-3’UTR and ERCC1-118 polymorphism status results in higher response rates and longer progression-free survival (PFS) as well as OS.
format Online
Article
Text
id pubmed-5493718
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer Vienna
record_format MEDLINE/PubMed
spelling pubmed-54937182017-07-17 ASCO 2016 – update colorectal liver metastases Kaczirek, Klaus Memo Short Review This short review summarizes the most relevant data on colorectal liver metastases (CLM) presented at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO). For this update, congress abstracts were grouped into three clinically relevant scenarios: CLM that are deemed upfront resectable, borderline resectable, and primarily unresectable. According to a large registry study, small, upfront resectable, solitary CLM should be resected using a parenchymal sparing technique. A prospective noninterventional study suggested that chemotherapy plus the anti-VEGF (vascular endothelial growth factor) antibody bevacizumab is effective and well tolerated in patients with borderline resectable CLM. In the setting of CLM deemed initially unresectable, a phase 2 study reported superior outcomes in terms of liver metastases resection rates as well as overall survival (OS) in patients receiving a chemotherapy triplet (FOLFIRINOX) plus a targeted agent as compared to FOLFIRI or FOLFOX4 with the same targeted therapy. Finally, a study suggested that tailoring first-line chemotherapy according to TYMS-3’UTR and ERCC1-118 polymorphism status results in higher response rates and longer progression-free survival (PFS) as well as OS. Springer Vienna 2017-01-17 2017 /pmc/articles/PMC5493718/ /pubmed/28725278 http://dx.doi.org/10.1007/s12254-016-0308-y Text en © The Author(s) 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Short Review
Kaczirek, Klaus
ASCO 2016 – update colorectal liver metastases
title ASCO 2016 – update colorectal liver metastases
title_full ASCO 2016 – update colorectal liver metastases
title_fullStr ASCO 2016 – update colorectal liver metastases
title_full_unstemmed ASCO 2016 – update colorectal liver metastases
title_short ASCO 2016 – update colorectal liver metastases
title_sort asco 2016 – update colorectal liver metastases
topic Short Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5493718/
https://www.ncbi.nlm.nih.gov/pubmed/28725278
http://dx.doi.org/10.1007/s12254-016-0308-y
work_keys_str_mv AT kaczirekklaus asco2016updatecolorectallivermetastases